These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6136059)

  • 1. A depot neuroleptic withdrawal study neurological effects.
    Wistedt B; Wiles D; Jørgensen A
    Psychopharmacology (Berl); 1983; 80(2):101-5. PubMed ID: 6136059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.
    Wistedt B
    Acta Psychiatr Scand; 1981 Jul; 64(1):65-84. PubMed ID: 7032224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency.
    Wistedt B; Jørgensen A; Wiles D
    Psychopharmacology (Berl); 1982; 78(4):301-4. PubMed ID: 6818587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot neuroleptics: side effects and safety.
    Marder SR
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in extrapyramidal symptoms following anticholinergic drug withdrawal.
    Perenyi A; Gardos G; Samu I; Kallos M; Cole JO
    Clin Neuropharmacol; 1983 Mar; 6(1):55-61. PubMed ID: 6133613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia.
    Dufresne RL; Wagner RL
    J Clin Psychiatry; 1988 Nov; 49(11):435-8. PubMed ID: 2903141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depot neuroleptic therapy: an underutilized treatment option.
    Glazer WM; Kane JM
    J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Schizophr Res; 1991; 4(2):109-20. PubMed ID: 1674881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tardive dyskinesia in schizophrenic outpatients: prevalence and significant variables.
    Ezrin-Waters C; Seeman MV; Seeman P
    J Clin Psychiatry; 1981 Jan; 42(1):16-22. PubMed ID: 6109715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study.
    Dencker SJ; Lepp M; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():64-76. PubMed ID: 6105763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
    Ben Hadj Ali B; Dogui M; Ben Ammou S; Lôo H
    Encephale; 1995; 21(3):209-15. PubMed ID: 7649071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia in outpatients on depot phenothiazine.
    Neehall J
    West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
    Kane J; Quitkin F; Rifkin A; Klein DF
    Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Movement disorders in patients treated with long-acting injectable antipsychotic drugs.
    Bransgrove LL; Kelly MW
    Am J Hosp Pharm; 1994 Apr; 51(7):895-9. PubMed ID: 7912473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of long term dopamine D2 receptor blockade after depot neuroleptics.
    Harasko-van der Meer C; Brücke T; Wenger S; Fischer P; Deecke L; Podreka I
    J Neural Transm Gen Sect; 1993; 94(3):217-21. PubMed ID: 7907218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.